Implications of Heart Rate in Patients with Left Ventricular Assist Devices.


Journal

International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240

Informations de publication

Date de publication:
2022
Historique:
entrez: 31 1 2022
pubmed: 1 2 2022
medline: 5 2 2022
Statut: ppublish

Résumé

Optimal heart rate (HR) is a promising therapeutic target in patients with heart failure with reduced ejection fraction. Nevertheless, the implication of optimal HR in patients with left ventricular assist devices (LVAD) remains unknown. The cohort included consecutive patients with sinus rhythm undergoing LVAD implantation between 2014 and 2018. Ideal HR was calculated as follows: 93 - 0.13 × (deceleration time [msec]). The impact of "HR difference," defined as an HR difference between the actual HR at discharge and the calculated ideal HR, on the 1-year mortality and heart failure readmissions was investigated. A total of 143 patients (55 years old, 101 men) was identified and tertiled considering their HR differences: (1) the optimal HR group (n = 49; HR difference < 27 bpm), (2) the suboptimal HR group (n = 47; HR difference = 27-42 bpm), and (3) the nonoptimal HR group; HR difference (n = 47; HR difference > 43 bpm). The nonoptimal HR group had a significantly higher 1-year cumulative incidence of the primary endpoint compared with the optimal HR group (38% versus 16%, P = 0.029) with a hazard ratio of 1.69 (95% confidence interval 1.02-2.57) adjusted for 6 potential confounders. In conclusion, nonoptimized HR negatively affected clinical outcomes in LVAD patients. The implication of deceleration time-guided HR optimization in LVAD patients should be further investigated.

Identifiants

pubmed: 35095077
doi: 10.1536/ihj.21-468
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-61

Auteurs

Teruhiko Imamura (T)

Second Department of Internal Medicine, University of Toyama.
Department of Medicine, University of Chicago Medical Center.

Koichiro Kinugawa (K)

Second Department of Internal Medicine, University of Toyama.

Nikhil Narang (N)

Advocate Christ Medical Center.

Hidefumi Nishida (H)

Department of Surgery, University of Chicago Medical Center.

Sean Pinney (S)

Department of Medicine, University of Chicago Medical Center.

Valluvan Jeevanandam (V)

Department of Surgery, University of Chicago Medical Center.

Takeyoshi Ota (T)

Department of Surgery, University of Chicago Medical Center.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH